Dosage of subcutaneous injection of evantumumab (Rybrevant Faspro)

Subcutaneous evantumumab (Rybrevant Faspro) is a subcutaneous drug used to treat non-small cell lung cancer (NSCLC). Its dosage and administration method are significantly different from the intravenous form. The following is the recommended dosage and usage of this drug for the reference of doctors and patients.

1. How to use: This drug is designed for subcutaneous use. It is recommended that the injection site is the abdomen, and the injection time is about 5 minutes. The recommended dose is adjusted based on the patient's baseline weight, and relevant pretreatment medications should also be considered before treatment.

2. Recommended dosage

For patients receiving combination therapy with carboplatin and pemetrexed who weigh less than 80 kg, the recommended dose is 1,600 mg of evantumumab with 20,000 units of hyaluronidase, administered initially on day 1 of week 1, followed by weekly dosing in weeks 2 and 3 for a total of two doses. Starting from week 4, dosing is given every 3 weeks. If patients weigh 80 kg and above, the recommended dose is 2240 mg of evantumumab and 28000 units of hyaluronidase, with the same dosing regimen as for patients weighing less than 80 kg.

In addition, when used in combination with lanzutinib or as monotherapy, in patients weighing less than80 kg, the recommended dose is 1,600 mg of evantumumab and 20,000 units of hyaluronidase administered once per week from week 1 to week 4 for a total of 4 doses, and then every 2 weeks starting from week 5. For patients weighing 80 kg and above, the recommended dose is 2240 mg of evantumumab and 28000 units of hyaluronidase. The dosage regimen is also once a week from week 1 to week 4, and then once every 2 weeks.

Of note, if a patient's weight changes during subsequent treatment, dose adjustment is generally not required.

Reference materials:https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT+Faspro-pi.pdf